Vericiguat for Heart Failure With Reduced Ejection Fraction After Myocardial Infarction
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Vericiguat Oral Tablet [Verquvo], Prescription Drugs.
- Who it may be relevant to
- Registry conditions: HFrEF - Heart Failure With Reduced Ejection Fraction, Myocardial Infarction (MI). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Vericiguat for Ventricular Remodeling in Patients With Heart Failure With Reduced Ejection Fraction After Myocardial Infarction
Overview
The effects of vericiguat on cardiac remodeling in patients with chronic stable heart failure after myocardial infarction have not been reported. This project aims to clarify the efficacy and safety of vericiguat in patients with chronic heart failure after myocardial infarction. Patients with chronic stable heart failure with reduced ejection fraction after myocardial infarction in the electronic medical records of Qilu Hospital of Shandong University will be selected and divided into two groups: the treatment group received vericiguat in addition to conventional treatment and the control group received conventional treatment only. After 12-month treatment, the effects of vericiguat on cardiac remodeling and function and cardiovascular adverse events will be evaluated. The results are helpful to provide a new treatment strategy for chronic heart failure after myocardial infarction.
Interventions
- Drug Vericiguat Oral Tablet [Verquvo]
Vericiguat in addition to conventional treatment - Drug Prescription Drugs
Conventional treatment only
Primary outcome measures
- LVEDVI=LVEDV/BSA [Time frame: From baseline to the end of 12-month treatment]
Eligibility criteria
Inclusion criteria
- The history of acute myocardial infarction exceeds 3 months;
- Symptoms and signs of heart failure have been stable for more than one month;
- 18 years old or more;
- NYHA cardiac function classified as grade II\~IV;
- LVEF≤40%；
- NT-proBNP≥450pg/ml；
- All subjects or their guardians must sign the subject consent before entering the trial.
Exclusion criteria
- Patients with the following diseases: nonischemic cardiomyopathy; valvular heart disease; congenital heart disease; obstruction of left ventricular outflow tract; severe decompensated heart failure; active myocarditis or pericardial disease; end-stage liver and kidney diseases; malignant tumor;
- Mechanical complications of myocardial infarction;
- Unable to obtain primary outcome data.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 3 centers
- Qilu Hospital of Shandong University — Jinan
- Central Hospital Affiliated to Shandong First Medical University — Jinan
- The First Affiliated Hospital of Shandong First Medical University/Shandong Province Qianf — Jinan
Identifiers
NCT: NCT06717204 · Vericiguat for HFrEF